The estimated Net Worth of Kathryn E Wengel is at least $15.6 Million dollars as of 13 February 2024. Ms. Wengel owns over 651 units of Johnson & Johnson stock worth over $13,613,802 and over the last 6 years she sold JNJ stock worth over $1,994,400. In addition, she makes $0 as Executive Vice President and Chief Global Supply Chain Officer at Johnson & Johnson.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Wengel JNJ stock SEC Form 4 insiders trading
Kathryn has made over 18 trades of the Johnson & Johnson stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 651 units of JNJ stock worth $107,298 on 13 February 2024.
The largest trade she's ever made was exercising 40,000 units of Johnson & Johnson stock on 10 June 2022 worth over $2,901,600. On average, Kathryn trades about 7,769 units every 73 days since 2019. As of 13 February 2024 she still owns at least 82,598 units of Johnson & Johnson stock.
You can see the complete history of Ms. Wengel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kathryn Wengel biography
Kathryn E Wengel is the Executive Vice President, Chief Global Supply Chain Officer of the Company. She has joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions across the global enterprise, in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. In 2010, Ms. Wengel became the first Chief Quality Officer of the Company. In 2014, she was promoted to Vice President, Johnson & Johnson Supply Chain. In July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee.
How old is Kathryn Wengel?
Kathryn Wengel is 54, she's been the Executive Vice President and Chief Global Supply Chain Officer of Johnson & Johnson since 2018. There are 25 older and 5 younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Ronald Williams, 70, who is the Independent Director.
What's Kathryn Wengel's mailing address?
Kathryn's mailing address filed with the SEC is ONE JOHNSON & JOHNSON PLAZA, , NEW BRUNSWICK, NJ, 08933.
Insiders trading at Johnson & Johnson
Over the last 22 years, insiders at Johnson & Johnson have traded over $59,929,946 worth of Johnson & Johnson stock and bought 21,998 units worth $2,578,685 . The most active insiders traders include Hubert Joly, Anne M Mulcahy, and Alex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of $4,572,436. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth $563,838.
What does Johnson & Johnson do?
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
What does Johnson & Johnson's logo look like?
Complete history of Ms. Wengel stock trades at Johnson & Johnson and Labcorp
Johnson & Johnson executives and stock owners
Johnson & Johnson executives and other stock owners filed with the SEC include:
-
Alex Gorsky,
Chairman of the Board, Chief Executive Officer -
Paulus Stoffels,
Vice Chairman- Executive Committee, Chief Scientific Officer -
Joaquin Duato,
Vice Chairman - Executive Committee -
Joseph Wolk,
Chief Financial Officer, Executive Vice President -
Jennifer Taubert,
Executive Vice President - Worldwide Chairman, Pharmaceuticals -
Michael Ullmann,
Executive Vice President, General Counsel -
Alex Gorsky,
Exec. Chairman -
Peter Fasolo,
Chief Human Resource Officer, Executive Vice President -
Dr. Paulus A. Stoffels M.D., Ph.D.,
Chief Scientific Officer -
Joaquin Duato,
CEO & Director -
Joseph J. Wolk CPA,
Exec. VP & CFO -
Joseph J. Wolk C.P.A.,
Exec. VP & CFO -
Jennifer L. Taubert,
Exec. VP & Worldwide Chairman of Pharmaceuticals -
Anne Mulcahy,
Lead Independent Director -
Charles Prince,
Independent Director -
Mary Beckerle,
Independent Director -
Ronald Williams,
Independent Director -
D. Scott Davis,
Independent Director -
A. Eugene Washington,
Independent Director -
Jennifer Doudna,
Independent Director -
Mark McClellan,
Independent Director -
Ian Davis,
Independent Director -
Marillyn Hewson,
Independent Director -
Mark Weinberger,
Independent Director -
Hubert Joly,
Independent Director -
Christopher DelOrefice,
Vice President, Investor Relations -
Kathryn Wengel,
Executive Vice President, Chief Global Supply Chain Officer -
Michael Sneed,
Executive Vice President - Global Corporate Affairs and Chief Communication Officer -
Thibaut Mongon,
Executive Vice President, Worldwide Chairman, Consumer -
Ashley McEvoy,
Executive Vice President - Worldwide Chairman, Medical Devices -
Dr. Guy J. Lebeau M.D.,
Group Chairman of MD&D Bus. - EMEA -
Dr. Peter M. Fasolo Ph.D.,
Exec. VP & Chief HR Officer -
Michael H. Ullmann,
Exec. VP & Gen. Counsel -
Jessica Moore,
VP of Investor Relations -
Ashley Watson,
Chief Compliance Officer -
James Swanson,
Exec. VP & Global CIO -
Robert J. Decker Jr.,
Controller & Chief Accounting Officer -
James Cullen,
Director -
Stephen J Cosgrove,
-
Leo F Mullin,
Director -
Michael M E Johns,
Director -
Robert J Decker,
VP Corporate Controller -
Elizabeth Forminard,
Executive VP, General Counsel -
Ronald A Kapusta,
Controller, CAO -
Susan L Lindquist,
Director -
Gary J Pruden,
Exec VP, WW Chair, Med Devices -
William D Perez,
Director -
Jorge S. Mesquita,
Exec VP, WW Chair, Consumer -
Dominic J Caruso,
Chief Financial Officer -
Timothy Schmid,
EVP, WW Chair, MedTech -
Mary Sue Coleman,
Director -
David Satcher,
Director -
William C Weldon,
Chairman/CEO -
Arnold G Langbo,
Director -
Russell C Deyo,
Vice President, Administration -
Kaye I Foster Cheek,
VP, Human Resources -
Colleen A Goggins,
Member, Executive Committee -
Sherilyn S Mc Coy,
Member, Executive Committee -
Donald M Jr. Casey,
Member, Executive Committee -
Nicholas J Valeriani,
Vice President,Human Resources -
Christine A Poon,
Executive Committee Member -
Joseph C Scodari,
Executive Committee Member -
Steven Reinemund,
Director -
Ann Dibble Jordan,
Director -
Robert J Darretta,
Member, Executive Committee -
Per A Peterson,
Executive Committee Member -
Michael J Dormer,
Member, Executive Committee -
Joann Heffernan Heisen,
Member, Executive Committee -
Gerard N Burrow,
Director -
Henry B Schacht,
Director -
M Judah Folkman,
Director -
Roger S Fine,
Vice President General Counsel -
James T Lenehan,
Vice Chairman -
Brian D Perkins,
Executive Committee Member -
Robert N Wilson,
-
Nadja West,
Director -
Vanessa Broadhurst,
EVP, Global Corp Affairs -
Mathai Mammen,
EVP, Pharm, R&D -
William Hait,
EVP, Chief EI and Med Officer -
Darius Adamczyk,
Director -
James D. Swanson,
EVP, CIO -
John C Reed,
EVP, Innovative Medicine, R&D -
Paula A Johnson,
Director -
Eugene A. Woods,
Director